September registrations describe separate age groups and follow-up measures. Neither study has posted results.
SAN MATEO, California, October 20, 2026 | FITIGER News
Two newly posted University of Calgary study registrations set out plans to follow choking care in Alberta, Canada, separating people older than two from children aged two or younger. The ClinicalTrials.gov records first appeared on September 11 and September 14, 2026. Both list May 1 as the actual study start date. When checked on October 20, both were marked recruiting, with no results posted.
The planned enrollment is 640 for the older group and 381 for the younger group. These are estimates, not counts of people already studied. Both records give June 30, 2030 as estimated primary completion and December 31, 2030 as estimated study completion.
The records describe observational cohorts of people who experienced an out-of-hospital foreign-body airway obstruction, received an intervention, and were assessed by emergency medical services or subsequently attended an emergency department. They identify Cody Dunne as principal investigator and the University of Calgary as sponsor. Patients with abnormal airway anatomy, such as a tracheostomy, are excluded.
Recorded groups include standard first-aid interventions and a LifeVac airway clearance device group. This is a description of observed care, not an instruction to try every listed intervention at every age. FITIGER is not named in the listed groups, and these records do not establish a clinical result for any FITIGER model.
For someone comparing an anti choking device for adults, the inclusion criteria deserve a close read. These studies require EMS assessment or an emergency-department visit. They will not count every choking episode in the community, including incidents that resolve without medical contact.
Both studies list obstruction relief on day one as the primary outcome. Secondary measures include survival to discharge from acute care, survival with favorable neurological outcome and intervention-associated injury. The follow-up window for those secondary outcomes extends up to three months. The records give definitions for the measures; they do not yet provide outcome rates.
FITIGER's product-safety editorial analysis is that a claim about the best anti choking device must identify the outcome being compared. Removal of an obstruction, discharge alive and absence of injury cannot be swapped for one another. A headline percentage without its denominator, time point and patient group leaves a buyer unable to judge what it means.
For a suction device for choking, the sequence of care also matters. If someone receives several interventions, a report needs enough information to distinguish their order and the person's condition at each stage. An observational comparison does not randomly assign treatment. Differences in severity or in who receives a device can complicate interpretation. Those are questions to examine when results appear, not flaws this article has demonstrated in the Calgary studies.
FITIGER's public EasyPumpVac human-factors page provides a smaller, different kind of evidence. It describes simulated use involving lay participants and healthcare professionals, with FAC01-B identified as the representative device. Three published excerpts last 9, 66 and 46 seconds. Those numbers are clip lengths, not choking-clearance times or survival measurements.
The nine-second excerpt begins after setup. Another shows repeated handling; the preparation excerpt does not establish independent task completion. Before treating a short recording as a speed claim, ask where it starts and which steps it leaves out. The public human-factors summary and observation clips explain those limits; confidential methods and underlying data are not published there. The excerpts do not establish real-emergency effectiveness, a completion rate or evidence for FoldPumpVac.
For U.S. buyers, study registration is also separate from product marketing authorization. A listing on ClinicalTrials.gov is not government approval of a product or its science. FITIGER's FDA authorization verification guide explains why exact device records matter. The Canadian registrations do not settle that question for a FITIGER product.
Emily, identified as a customer from Austin in a June 24, 2025 account on FITIGER's website, describes taking a foldable FITIGER unit on a camping trip. For a portable choking rescue device, that is a relevant account of packing and carrying. It is not a report of treatment, and no rescue outcome can be calculated from it.
A choking first aid kit needs a plan that works when caregivers or locations change. Confirm the exact model's intended users and storage conditions, keep access information clear, and follow age-appropriate first-aid training. FITIGER's family readiness planning page connects those practical decisions with home and travel arrangements; it is not proof that a particular device suits every child.
The Canadian Red Cross distinguishes training that covers adults from training that also covers children and babies. Choose training appropriate to the people in your care. For U.S. readers, the FDA advises established choking rescue protocols first, with a device as a second option if standard protocols are unsuccessful. Do not delay emergency action to obtain equipment or wait for research results.
Readers following this research should look for reported enrollment, changes to the study plan and published findings. Reaching a projected completion date will not, by itself, tell us whether an intervention worked.
Sources checked October 20, 2026. FITIGER sells anti-choking products. This report's product-safety and technical commentary is brand editorial analysis of public records, not an independent clinical review, a new experiment or a claim of study involvement. The public usability page's October 19 update is not presented as a new trial date. Customer feedback and simulated use are kept separate from clinical outcomes. All three images are generated editorial illustrations. This article does not replace professional medical advice, emergency services, certified first-aid training or product-specific regulatory review.
